Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH-COVID: RAS Inhibitors in COVID-19
NCT04493359Phase 3Terminated
- Sponsor
- Universidade de São Paulo
- Start
- Jul 2020
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hypertension (HTN) (2 arms), sponsored by Universidade de São Paulo. Primary endpoint: Need for ICU admission or mortality at 30 days. Started Jul 2020; status: terminated.
02
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04493359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493359.